Semiconductor stocks recently broke down, removing key support for AI-driven equity indices and signaling the end of the AI stock bubble. While AI-related valuations remain high and unattractive, the broader market selloff outside the AI sector has created more appealing investment opportunities. The analysts suggest focusing on undervalued sectors like BDCs and REITs for better income and capital preservation. This shift highlights a move away from speculative AI trades toward more conservative, income-generating investments.
The hunt for red in October is contextualized by Pluang's Technology sector data as of Oct 20, 2026 01:32 WIB. Among 150 priced US tech stocks, 120 rose and 30 fell today. Notable movers include AEHR (Aehr Test Systems) with a price of USD 63.20 and a 1-day gain of +4.29%, MRVL (Marvell Technology Inc) at USD 236.54 up +3.83%, and EPAM (EPAM Systems Inc) at USD 126.81 with a +3.78% increase. Typical hold times on Pluang range from 16 to 43 days, with AEHR showing strong buy interest at 85%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
